Class Action Lawsuit Filed Against ARS Pharmaceuticals Over Insurance Coverage for Neffy
A class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by Pomerantz LLP over alleged securities fraud and other unlawful business practices involving the company's epinephrine nasal spray product 'neffy.' The firm is urging investors who purchased or acquired shares during a specified period to contact them before October 5, 2026, for potential inclusion in the lawsuit. On June 24, 2026, ARS announced it did not secure expanded insurance coverage for neffy through CVS Caremark by its July 1 deadline, impacting summer and back-to-school allergy season availability. This news led to a significant drop in ARS's stock price of $2.52 per share (or 23.91%) on June 25, closing at $8.02 per share. The lawsuit highlights concerns over whether the company or its officers misrepresented information regarding insurance coverage and product availability. Pomerantz LLP is a well-known firm in securities litigation with offices across multiple global locations. The class action seeks to hold ARS accountable for any misleading statements that may have affected investor decisions.
Tickers: $SPRY